{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:40:17Z","timestamp":1787010017720,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To analyze retinal perfusion using ultrawide-field fluorescein angiography and optical coherence tomography angiography, in patients with central retinal vein occlusion treated by intravitreal injection of aflibercept.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Single-arm, multicenter, prospective, observational study. Treatment-naive eyes with central retinal vein occlusion initiated therapy with aflibercept. Ultrawide-field fluorescein angiography with correction of projection distortion and optical coherence tomography angiography were performed at baseline (M0), M3, M12, and M24.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Fifty-six eyes were included. Visual acuity improved by 16 ETDRS letters at M12 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), while mean central subfield thickness decreased from 801\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m at M0 to 352\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m at M12 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). The ischemic index on ultrawide-field fluorescein angiography increased from 17% at M0 to 23% at M3, and to 36% at M24. Ischemic central retinal vein occlusion accounted for 18% at M0, 25% at M3, and 39% at M24 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). Vascular leakage was only present in 21% of eyes at M12. The density of the superficial and deep capillary plexus remained stable, but the foveal avascular zone enlarged from 0.37 mm\n                      <jats:sup>2<\/jats:sup>\n                      at M0 to 0.61 mm\n                      <jats:sup>2<\/jats:sup>\n                      at M24 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02). No cases of reperfusion were observed. The mean number of injections at M12 was 7.0 \u00b1 3.6.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Changes in retinal perfusion were characterized by worsening perfusion in the periphery, while macular capillaries maintained a generally stable density at M24, even in ischemic central retinal vein occlusion. These findings support the need for regular monitoring of peripheral retinal perfusion in treated patients to detect silent progression of nonperfusion, which may lead to neovascular complications, while visual acuity is maintained over the long term, likely due to the preserved macular capillary density.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004425","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T17:00:06Z","timestamp":1739293206000},"page":"1151-1159","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["CHANGE IN RETINAL PERFUSION WITH AFLIBERCEPT FOR CENTRAL RETINAL VEIN OCCLUSION"],"prefix":"10.1097","volume":"45","author":[{"given":"Agn\u00e8s","family":"Glacet-Bernard","sequence":"first","affiliation":[{"name":"Centre Hospitalier Intercommunal de Cr\u00e9teil & H\u00f4pital Henri Mondor, Paris-Est Cr\u00e9teil (UPEC-Paris XII) University, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Girmens","sequence":"additional","affiliation":[{"name":"H\u00f4pital National des 15-20, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Coscas","sequence":"additional","affiliation":[{"name":"Centre Ophtalmologique de l\u2019Od\u00e9on, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Nghiem-Buffet","sequence":"additional","affiliation":[{"name":"Centre Ophtalmologique d\u2019Imagerie et de Laser, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Morel","sequence":"additional","affiliation":[{"name":"Centre Monticelli Paradis Ophtalmologie, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Erginay","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Lariboisi\u00e8re and St Louis Hospital, Paris, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Weber","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Nantes, Nantes Universit\u00e9, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Wang","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Intercommunal de Cr\u00e9teil & H\u00f4pital Henri Mondor, Paris-Est Cr\u00e9teil (UPEC-Paris XII) University, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Jung","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Intercommunal de Cr\u00e9teil & H\u00f4pital Henri Mondor, Paris-Est Cr\u00e9teil (UPEC-Paris XII) University, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon-Yves","family":"Cohen","sequence":"additional","affiliation":[{"name":"Centre Ophtalmologique d\u2019Imagerie et de Laser, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Aubert","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Intercommunal de Cr\u00e9teil & H\u00f4pital Henri Mondor, Paris-Est Cr\u00e9teil (UPEC-Paris XII) University, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Blanco-Garavito","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Intercommunal de Cr\u00e9teil & H\u00f4pital Henri Mondor, Paris-Est Cr\u00e9teil (UPEC-Paris XII) University, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric H.","family":"Souied","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Intercommunal de Cr\u00e9teil & H\u00f4pital Henri Mondor, Paris-Est Cr\u00e9teil (UPEC-Paris XII) University, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Miere","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Intercommunal de Cr\u00e9teil & H\u00f4pital Henri Mondor, Paris-Est Cr\u00e9teil (UPEC-Paris XII) University, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":"Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ophtha.2013.08.012","article-title":"Intravitreal aflibercept injection for Macular\u00a0Edema resulting from central retinal Vein\u00a0Occlusion: one-year results of the phase 3 GALILEO study","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ophtha.2012.01.042","article-title":"Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study","volume":"119","author":"Boyer","year":"2012","journal-title":"Ophthalmology"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archopht.1997.01100150488006","article-title":"Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group","volume":"115","year":"1997","journal-title":"Arch Ophthalmo"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0161-6420(96)30653-2","article-title":"Prognostic factors for retinal vein occlusion: prospective study of 175 cases","volume":"103","author":"Glacet-Bernard","year":"1996","journal-title":"Ophthalmology"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.ophtha.2012.09.032","article-title":"Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion","volume":"120","author":"Campochiaro","year":"2013","journal-title":"Ophthalmology"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","article-title":"Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study","volume":"123","author":"Clark","year":"2016","journal-title":"Ophthalmology"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1097\/IAE.0000000000000191","article-title":"Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial","volume":"34","author":"Brown","year":"2014","journal-title":"Retina"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1097\/IAE.0000000000002993","article-title":"Nonperfusion assessment in retinal vein occlusion: comparison between ultra-widefield fluorescein angiography and widefield optical coherence tomography angiography","volume":"41","author":"Glacet-Bernard","year":"2021","journal-title":"Retina"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ajo.2017.07.015","article-title":"Retinal nonperfusion in the posterior Pole is associated with increased risk of neovascularization in central retinal vein occlusion","volume":"182","author":"Nicholson","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1097\/IAE.0000000000001737","article-title":"Optical coherence tomography angiography in retinal vein occlusion: correlations between macular vascular density, visual acuity, and peripheral nonperfusion area on fluorescein angiography","volume":"38","author":"Seknazi","year":"2018","journal-title":"Retina"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1097\/IAE.0000000000001334","article-title":"Qualitative and quantitative follow-up using optical coherence tomography angiography of retinal vein occlusion treated with anti-vegf: optical coherence tomography angiography follow-up of retinal vein occlusion","volume":"37","author":"Sellam","year":"2017","journal-title":"Retina"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ajo.2012.09.026","article-title":"Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study","volume":"155","author":"Brown","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40123-019-0184-8","article-title":"Real-life evidence for using a treat-and-extend injection regime for patients with central retinal vein occlusion","volume":"8","author":"Eleftheriadou","year":"2019","journal-title":"Ophthalmol Ther"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"8310350","DOI":"10.1155\/2018\/8310350","article-title":"Efficacy and safety of an aflibercept treat-and-extend regimen in treatment-na\u00efve patients with macular oedema secondary to central retinal vein occlusion (CRVO): a prospective 12-month, single-arm, multicentre trial","volume":"2018","author":"Garcia-Arumi","year":"2018","journal-title":"J Ophthalmol"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3928\/23258160-20180329-08","article-title":"Longitudinal quantification of retinal nonperfusion in the macula of eyes with retinal vein occlusion receiving anti-VEGF therapy: secondary analysis of the WAVE randomized trial","volume":"49","author":"Ou","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/s41433-021-01553-7","article-title":"The clinical relevance of ultra-widefield angiography findings in patients with central retinal vein occlusion and macular oedema receiving anti-VEGF therapy","volume":"36","author":"Nicholson","year":"2022","journal-title":"Eye"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ophtha.2015.10.030","article-title":"Changes in retinal nonperfusion associated with suppression of vascular endothelial growth factor in retinal vein occlusion","volume":"123","author":"Mir","year":"2016","journal-title":"Ophthalmology"},{"key":"R20-20250527","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ophtha.2010.04.019","article-title":"Natural history of visual outcome in central retinal vein occlusion","volume":"118","author":"Hayreh","year":"2011","journal-title":"Ophthalmology"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1159\/000530294","article-title":"Real-world outcomes of ranibizumab treatment in French patients with visual impairment due to macular edema secondary to retinal vein occlusion: 24-month results from the BOREAL-RVO study","volume":"66","author":"Glacet-Bernard","year":"2023","journal-title":"Ophthalmic Res"},{"key":"R22-20250527","doi-asserted-by":"crossref","first-page":"e000249","DOI":"10.1136\/bmjophth-2018-000249","article-title":"Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors","volume":"4","author":"Spooner","year":"2019","journal-title":"BMJ Open Ophthalmol"},{"key":"R23-20250527","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.3390\/jcm10071423","article-title":"Longitudinal changes on optical coherence tomography angiography in retinal vein occlusion","volume":"10","author":"Tripathy","year":"2021","journal-title":"J Clin Med"},{"key":"R24-20250527","doi-asserted-by":"crossref","first-page":"100267","DOI":"10.1016\/j.xops.2022.100267","article-title":"Deep capillary plexus as biomarker of peripheral capillary nonperfusion in central retinal vein occlusion","volume":"3","author":"Battaglia Parodi","year":"2023","journal-title":"Ophthalmol Sci"},{"key":"R25-20250527","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.3390\/diagnostics13193100","article-title":"An analysis of optical coherence tomography angiography (OCT-A) perfusion density maps in patients treated for retinal vein occlusion with intravitreal aflibercept","volume":"13","author":"\u015apiewak","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"R26-20250527","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1167\/iovs-16-20648","article-title":"Retinal hemodynamics seen on optical coherence tomography angiography before and after treatment of retinal vein occlusion","volume":"57","author":"Suzuki","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R27-20250527","doi-asserted-by":"crossref","first-page":"1267492","DOI":"10.3389\/fmed.2023.1267492","article-title":"Changes in foveal avascular zone area and retinal vein diameter in patients with retinal vein occlusion detected by fundus fluorescein angiography","volume":"10","author":"Liao","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"R28-20250527","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1007\/s00417-024-06410-3","article-title":"Changes in wider field swept-source OCT angiography vascular metrics with anti-vascular endothelial growth factor therapy in central retinal vein occlusion","volume":"262","author":"Razavi","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R29-20250527","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","article-title":"Efficacy and safety of faricimab for ME due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials","volume":"131","author":"Tadayoni","year":"2024","journal-title":"Ophthalmology"},{"key":"R30-20250527","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00417-023-06343-3","article-title":"Relationship between ischemic index, leakage index, and ME in branch retinal vein occlusion","volume":"262","author":"Sun","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R31-20250527","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.ophtha.2019.06.022","article-title":"Widefield OCT-angiography and fluorescein angiography assessments of nonperfusion in diabetic retinopathy and edema treated with anti-vascular endothelial growth factor","volume":"126","author":"Couturier","year":"2019","journal-title":"Ophthalmology"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T10:47:07Z","timestamp":1748342827000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004425"}},"subtitle":["The Two-Year Prospective Observational HERMES Study"],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004425","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}